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PHA306 – Advanced Pharmaceutics 
DURATION 
 
Reading Time: 10 minutes 
Writing Time: 120 minutes 
 
INSTRUCTIONS TO CANDIDATES 
The exam consists of 4 Sections (A, B, C & D). All sections need to be answered in the 20-page 
booklet provided 
Section A ( 1-8): 33 marks 
Section B (1-6):  26 marks 
Section C (1-9):  34 marks 
Section D (1-7): 27 marks 
Total marks of the exam: 120 marks 
EXAM CONDITIONS 
You may begin writing from the commencement of the examination session.  The reading time indicated above is 
provided as a guide only. 
This is a CLOSED BOOK examination 
Any non-programmable calculator is permitted 
No handwritten notes are permitted 
No dictionaries are permitted 
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Section A (33 marks) 
 
1. “During heat sterilization, microbial killing occurs in an exponential fashion”.  Explain this statement. 
(2 marks) 
 
2. The following table contain the D-values for two types of bacteria at different temperatures. 
 
Bacteria Type D110 D120 
A 6 minutes 2 minutes 
B 10 minutes 8 minutes 
 
I. Which type of bacteria is considered more resistant to heat sterilization and why? 
(2 marks) 
II. Calculate Q10 (temperature coefficient) for both bacteria and explain what it means. 
(3 marks) 
 
3. What is “thermal death time”? What are the factors that affect thermal death time?  
(5 marks) 
 
4. Mention the factors that can affect microbial killing through disinfection process. 
(5 marks) 
 
5. Define “sterility assurance level”. 
(2 marks) 
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7. Compare between the following sterilization methods in relation to the mechanism of microorganism 
inactivation. 
(5 marks) 





    
 
8. Compare between membrane and depth filters. 
(5 marks) 
 
END of Section A 
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Section B (26 marks) 
1. Mention the advantages of parenteral route of drug administration.  
(5 marks) 
 
2. What is the meaning of “compatible via Y-site” based on the “Australian injectable drugs handbook”?  
(2 marks) 
3. Explain the following incompatibilities: 
 
I. Diluting diazepam injection beyond four-folds produces white precipitate.  
(2 marks) 




4. A  pharmacist  receives  a  medication  order  for  300,000  units  of penicillin  G  potassium  to  be  added  
to  500 mL of  D5W (Dextrose 5% in Water).  The directions  on  the  1,000,000-unit  package  state  that  
if  1.6 ml  of solvent  are  added,  the  constituted  solution  will  measure  2 ml. How   many   millilitres   of   
the   constituted   solution   must   be withdrawn and added to the D5W? If the medication should be 
infused over half an hour, what is the infusion rate?  
(4 marks) 
 
5. Sterile compounding requires a strictly controlled environment 
I. Define “clean room”. What is the main principle in classifying clean rooms? 
(3 marks) 
 
II. What is “ante-room”? 
(2 marks) 
 
III. “Laminar airflow work bench (LAWB) is sufficient to achieve ISO Class 5 clean environment”. 
Explain this statement. 
(2 marks) 
 
6. In relation to the preparation of compounded sterile IV admixtures, what is the definition of 
“contamination”? What are the possible sources of contamination?  
(4 marks) 
 
END of Section B   
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Section C (34 marks) 
1. Mini Nutrition Assessment (MNA) questionnaire is one of the screening tools used to assess the 
nutritional status of elderly patients. Mention FOUR elements/questions used in this screening tool.  
(4 marks) 
 








4. What are the advantages of 3 in 1 TPN formulation? 
(3 marks) 
 
5. Explain why ophthalmic drops have poor bioavailability. 
(4 marks) 
 




7. In relation to inhalation therapy, explain how particle size distribution plays an important role in 
determining the drug efficacy and toxicity.  
(3 marks) 
 




9. What are the basic components of pressurised metered dose inhalers (pMDIs).  
(4 marks) 
END of Section C 
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Section D (27 marks) 
1. Mention all useful parameters used to assess drug bioavailability.  
(5 marks) 
 




3. Mention FIVE criteria for establishing a bioequivalence requirement as imposed by FDA?  
(5 marks) 
 
4. Compare between small-molecule drugs and biological drugs. 
(5 marks) 
 
5. During the manufacturing of a biological drug, any modifications in certain steps can alter the product’s 




6. When a biological drug can be considered as biosimilar?  
(3 marks) 
 
7. Mention THREE acceptable differences in a biosimilar drug.  
(3 marks) 
 
END of Section D 
END of Exam Paper 
